These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 8243155)

  • 41. Comparative analysis of the maternal and umbilical interleukin-8 levels in normal pregnancies and in pregnancies complicated by preeclampsia with intrauterine normal growth and intrauterine growth retardation.
    Laskowska M; Laskowska K; Leszczyńska-Gorzelak B; Oleszczuk J
    J Matern Fetal Neonatal Med; 2007 Jul; 20(7):527-32. PubMed ID: 17674266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The treatment of intrauterine growth retardation with ant polyrhachis vicina roger].
    Duan T; Bi N; Huang M
    Zhonghua Fu Chan Ke Za Zhi; 1999 May; 34(5):290-2. PubMed ID: 11326937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical study on effect of Chinese herbal medicine for supplementing kidney and qi and activating blood circulation in treating intrauterine growth retardation of fetus].
    Huang G; Shu Y; Ye W
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1999 Aug; 19(8):466-9. PubMed ID: 11783225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Longitudinal quantification of uterine artery blood volume flow changes during gestation in pregnancies complicated by intrauterine growth restriction.
    Konje JC; Howarth ES; Kaufmann P; Taylor DJ
    BJOG; 2003 Mar; 110(3):301-5. PubMed ID: 12628272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Placental vessel morphometry in growth retardation and increased resistance of the umbilical artery Doppler flow.
    Mitra SC; Seshan SV; Riachi LE
    J Matern Fetal Med; 2000; 9(5):282-6. PubMed ID: 11132583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neonatal morbidity and mortality in intrauterine growth restricted (IUGR) pregnancies is predicated upon prenatal diagnosis of clinical severity.
    Marconi AM; Ronzoni S; Vailati S; Bozzetti P; Morabito A; Battaglia FC
    Reprod Sci; 2009 Apr; 16(4):373-9. PubMed ID: 19087980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An animal model of intrauterine growth retardation induced by synthetic thromboxane a(2).
    Hayakawa M; Takemoto K; Nakayama A; Saito A; Sato Y; Hasegawa M; Ieda K; Mimura S
    J Soc Gynecol Investig; 2006 Dec; 13(8):566-72. PubMed ID: 17110136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of essential fatty acids preparation in the treatment of intrauterine growth retardation.
    Zhang L
    Am J Perinatol; 1997 Oct; 14(9):535-7. PubMed ID: 9394162
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The utero-placental circulation, eugenics and the prevention and treatment of high risk pregnancies.
    Wu XR; Li Y; Yang DS; Han BJ; Si YZ; Shan ZZ; Ma TY; Wen LZ; Sun YP; Huang YP
    J Tongji Med Univ; 1994; 14(1):1-6. PubMed ID: 7877185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicenter trial of the therapeutic effect of a newly developed antiplatelet agent, satigrel, on biopsy-proven chronic rejection after kidney transplantation.
    Teraoka S; Ota K; Tanabe K; Takahashi K; Toma H; Yasumura T; Yoshimura N; Oka T; Takahara S; Okuyama A; Haba T; Uchida K; Sugiyama S; Ohshima S; Sato T; Okazaki H; Morozumi K
    Transplant Proc; 1997; 29(1-2):266-71. PubMed ID: 9122990
    [No Abstract]   [Full Text] [Related]  

  • 51. Synthesis, oral bioavailability evaluation and antiplatelet aggregation activity of three derivatives of 3,4‑dihydroxyacetophenone.
    Sun N; Qu M; Wang M; Lv Y; Wei L; Duan Y
    Int J Mol Med; 2020 Mar; 45(3):919-930. PubMed ID: 31985017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Dosage of acetylsalicylic acid in the prevention and therapy of intrauterine growth retardation].
    Burnog T
    Ceska Gynekol; 1997 Feb; 62(1):9-11. PubMed ID: 9410426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physiological effects of autotoxicity due to DHAP stress on Picea schrenkiana regeneration.
    Yang L; Ruan X; Jiang D; Zhang J; Pan C; Wang Q
    PLoS One; 2017; 12(5):e0177047. PubMed ID: 28481896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth hormone treatment in patients with intrauterine growth retardation.
    Lanes R
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1345-6. PubMed ID: 10720090
    [No Abstract]   [Full Text] [Related]  

  • 55. [Effect of 3,4-dihydroxyacetophenone on platelet aggregation in normal pregnancy and pregnancy induced hypertension].
    Sun YP
    Zhonghua Fu Chan Ke Za Zhi; 1992 Jan; 27(1):9-11, 57. PubMed ID: 1505279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Study on relativity between oxygen free radical and thromboxane B2, 6-keto-PGF1 alpha during ligustrazine treatment of intrauterine growth retardation].
    Xu J; Ma T; Wen L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1998 May; 18(5):265-8. PubMed ID: 11477921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effects of berberine on platelet aggregation and plasma levels of TXB2 and 6-keto-PGF1 alpha in rats with reversible middle cerebral artery occlusion].
    Wu JF; Liu TP
    Yao Xue Xue Bao; 1995; 30(2):98-102. PubMed ID: 7785438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of IGF-I on placental thromboxane and prostacyclin release in severe intrauterine growth retardation.
    Sorem KA; Siler-Khodr TM
    J Matern Fetal Med; 1997; 6(6):341-50. PubMed ID: 9438218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of 3,4-dihydroxyacetophenone treatment on intrauterine growth retardation].
    Huang YP; Ma TY
    Zhonghua Fu Chan Ke Za Zhi; 1993 Jun; 28(6):333-6, 380. PubMed ID: 8243155
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.